SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 87.30 |
Enterprise Value ($M) | 48.96 |
Book Value ($M) | 39.58 |
Book Value / Share | 2.37 |
Price / Book | 2.21 |
NCAV ($M) | 39.54 |
NCAV / Share | 2.36 |
Price / NCAV | 2.21 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.38 |
Return on Assets (ROA) | -0.40 |
Return on Equity (ROE) | -0.46 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 11.59 |
Current Ratio | 11.59 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 44.31 |
Assets | 44.35 |
Liabilities | 4.77 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 3.55 |
Operating Income | -17.22 |
Net Income | -14.88 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -10.29 |
Cash from Investing | -0.03 |
Cash from Financing | 16.03 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | DME Capital Management, LP | 9.90 | ||
13G/A | Hirschman Orin | 8.00 | 14.56 | |
13G/A | Vanguard Group Inc | 5.55 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
4,609 | 73,146 | 6.30 | |
13,486 | 54,860 | 24.58 | |
4,471 | 21,392 | 20.90 | |
11,372 | 79,802 | 14.25 | |
(click for more detail) |
Financial data and stock pages provided by
Fintel.io